Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
ALQA AH huge 8K
Any one can tell us why they mentioned 3 companies in the merge
1 - Alliqua BioMedical
2 - TO Pharmaceuticals LLC
3 - Tikun Olam Limited
I think this will ride big waves.
Yeah we will see... I still hold
Didn't look too promising today.. 3.5 mill tradable os. And over 15 times that volume and we sittingalmost exactly where we started .
Should've been over 10.00 on day one
Let’s see a move... I got Wayne’s many average 2,98
* * $ALQA Video Chart 11-29-18 * *
Link to Video - click here to watch the technical chart video
* * $ALQA Video Chart 11-28-18 * *
Link to Video - click here to watch the technical chart video
Multi day runner? Low float. Big news
Yup, good possibility.
Looks like it might be time to get back in...
Buying more 3,40‘s and more bids in
Hope for squeeez
back to 3
ALQA still beasting..more legs coming
forming a nice long staircase to Heaven
ALQA $5.24 that was amazing from 2.28
The way things are going here, we may close @ high of the day > MASSIVE VOLUME!!!!!
100's of traders and 100's of tutes and investors at work here!
That is why we have seen a perfect steady ALQA climb since premarket and the open. You have to own the low floaters ahead of news if you can find them. They are best right after RS. ANY was awesome after their split because of news. I like TNXP now after toe 10 for 1 RS the float is so small it has been halted many time today already and then we have ALQA here today on small news this one has been running on air. Glad it has been steady all day here.
Great news,tiny float... lots a potential for mega squeeze
Let’s see buddy
Trading float is small > about 2 million shares > The OS is 5 million shares.
20,000 patients > ALQA going to $10+
About TO Pharmaceuticals
TO Pharmaceuticals LLC is a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics based on its proprietary cannabinoid product platform in a number of FDA-regulated clinical indications and in select OTC markets. TOP is exclusively licensed worldwide to utilize the pharmaceutical intellectual property developed by Tikun Olam Limited.
About Tikun Olam Limited
Tikun Olam ("repair the world" in Hebrew) is globally recognized as the pioneer of modern medical cannabis. Since 2010, its products have been the subject of ongoing clinical trials and have been relied upon to treat over 20,000 patients in Israel's regulated market for symptoms of conditions including cancer, PTSD, AIDS, epilepsy, Crohn's Disease/colitis, multiple sclerosis, cerebral palsy, chronic pain and neuropathy. The growing international network of Tikun Olam affiliates includes, among others, the USA's T.O. Global, LLC, Canada's MedReleaf and Australia's Medifarm.
,,,,,,,Yup I know. Happy with my $8,700 Profit~GOODLUCK!
6 plus soon IMO
11 million traded 5 million o/s interesting for sure
ALQA Float only 3.5m think about it! This baby is gonna blow! 40 million $ traded approximately already ??
SUPER LOW FLOATER > 5M OS and trading float is way less than 5M
ALQA 4 ducks!!!!!
,,,,,,,I think that's all she's gonna give. $3.61
well, the CFO is gone. Now clean the corner office, time for the CEO to go. The problem was not the CFO, it IS the CEO who has no business holding this position. This company is now trading at 1.45 per share, not much more time until we are back under a buck. Clean house while there is time.
just waiting for a real business leader to take charge. Hopefully this moron will get out of the way and let someone who understand business take the reins. Talk about a swamp that needs to be drained. CEO, and the puppets on the board. All need to go!
Volume on alert today
I took the time to read the report.... NOT A GOOD PICTURE. SELL SELL SELL. The only ones making money here are the upper management, they are watching out for themselves quit nicely. All the concerns about their ability to carry on as a business is written throughout the annual report. The board needs to clean house. The need to hire a businessman to lead what is left of this company. IMHO, time to sell and, if changes are made, buy it back in the .25 cent range. If no changes to management are made, this will continue to drift down and will become a penny stock once again. Nothing positive in the annual report, unless you are in upper management.
well, when will the board clean house and put in a management team that knows business? Once this thing breaks below a dollar the death spiral begins.
Well, guess 4 dollars did not happen. The reality, this company continues to sell assets to survive. Still seeing 1 dollar or less in the near future. Fire the president while there is time to save this company.
Followers
|
66
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
4871
|
Created
|
05/22/06
|
Type
|
Free
|
Moderators |
Alliqua's core transdermal delivery technology platform is designed to deliver drugs and other beneficial ingredients through the skin. Transdermal delivery has multiple advantages over conventional oral and injection delivery including:
In addition, Alliqua's patch technology can be utilized for the delivery of many drugs, including various proteins that have, until now, necessitated injections or intravenous infusions.
Alliqua intends to capitalize on its technology's other intrinsic benefits in various market verticals in the healthcare industry, including: wound healing, medical diagnostics and cosmeceuticals.
Alliqua, through its wholly owned subsidiary AquaMed, develops, manufactures and markets electron-beam cross-linked sheet gels for use as transdermal delivery of medication, topical application of non-prescription drugs, wound/burn dressings with and without active ingredients, components in certain medical devices, treatments, cosmetics and other commercial products.
Hydrogels are gel-like or colloidal substances made of water and solids. They can be created chemically (through a combination of ultra violet cross-linking and chemical interface), or by mixing polymer and water, and then exposing it to an electron beam creating a "sheet" of water. Alliqua believes that its hydrogels have a competitive advantage, in part due to the following product characteristics: painless adhesion to the human body, stability of form and composition, purity, reproducibility (manufacturing high quality product on a consistent basis), compatibility with active ingredients, and high water content.
Many of the products of Alliqua's competition feature physical characteristics which Alliqua believes are less desirable than its own hydrogels
Subsidiary | Products |
---|---|
Alliqua Biomedical | PHN Patch |
Hydress + Plus | |
Hydress | |
Aquamed Technologies | Contract Manufacturing Services |
Electrode Gel | |
Sheet Hydrogels | |
HepaLife Biosystems | HepaMate® |
RECENT HEADLINES
Thursday, November 15, 2012
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |